Multiple Myeloma | Topics

Doris K. Hansen, MD, Analyzes Real-World Experiences With Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma
September 23, 2022

Doris K. Hansen, MD, discussed results of an efficacy analysis examining the BCMA-directed CAR T-cell therapy idecabtagene vicleucel in real-world treatment of patients with relapsed/refractory multiple myeloma.

Teclistamab Induces Durable Responses in Phase 1/2 MajesTEC-1 Trial in R/R Multiple Myeloma
September 16, 2022

Results from the phase 1/2 MajesTEC-1 trial highlighted sustained responses when teclistamab was used to treat patients with relapsed/refractory multiple myeloma who are triple refractory.

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM
September 15, 2022

Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM
September 15, 2022

Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.

Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?
September 14, 2022

Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.

Comparing Combination Treatment Regimens in Transplant-Eligible NDMM
September 14, 2022

Matthew James Pianko, MD, provides an overview of the recently updated data from the GRIFFIN trial and the role of quadruplet versus triplet regimens in the treatment landscape of transplant-eligible newly diagnosed multiple myeloma.

Racial Disparities in the Treatment of Multiple Myeloma Patients
September 07, 2022

Drs Costa and Fonesca close out their discussion by highlighting the endemic racial disparities in multiple myeloma treatment.

Unmet Needs of Transplant-Ineligible Multiple Myeloma
September 07, 2022

A look at some of the unmet needs in transplant-ineligible multiple myeloma, particularly within the unfit patient population.

Recap: Dana-Farber Experts Review Treatment Options for Newly Diagnosed Multiple Myeloma
September 03, 2022

A panel of experts review real-world clinical scenarios to highlight recent advances in the management of multiple myeloma.

Elotuzumab Combo Significantly Improves Survival Vs Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma
September 01, 2022

Overall survival was significantly improved when elotuzumab was added to pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with lenalidomide and proteasome inhibitors